UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Dan Leonard has maintained a Neutral rating on 10x Genomics (NASDAQ:TXG) and lowered the price target from $52 to $30.

May 01, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Dan Leonard maintains a Neutral rating on 10x Genomics and lowers the price target from $52 to $30.
The reduction in the price target by UBS suggests a bearish outlook on the stock's short-term price potential, likely due to anticipated challenges or underperformance relative to the market. This adjustment could lead to a negative perception among investors, potentially impacting the stock's price negatively in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100